Low use of placebo in comparative drug rcts in migraine. Are clinical investigators unaware of basic methodological issues? by PC Tfelt-Hansen & A Hougaard
POSTER PRESENTATION Open Access
Low use of placebo in comparative drug rcts in
migraine. Are clinical investigators unaware of
basic methodological issues?
PC Tfelt-Hansen*, A Hougaard
From The European Headache and Migraine Trust International Congress
London, UK. 20-23 September 2012
If feasible placebo should be included in randomized,
controlled trials (RCTs) comparing two presumable
active drugs. Inclusion of placebo in comparative RCTs
was recommended generally by FDA in 1982, by the
International Headache Society for migraine in 1991,
and by the European Medicines Agency (EMEA) for
migraine in 2007.
Methods
We searched the world migraine literature from 2002 to
2011 for comparative drug RCTs of acute and prophy-
lactic treatment of migraine. We primarily registered
whether placebo was used or not.
Results
In 67 acute comparative RCTs placebo was included in
26 RCTs and in 26 prophylactic comparative RCTs pla-
cebo was included in only 2 RCTs [sic]. For the acute
RCTs without placebo (n=41) the median number of
patients was 76 (range: 12-2,436) and for acute RCTs
with placebo (505) the median number of patients was
505 (range 42 -2,113).
Discussion
Recommendations by FDA, IHS and EMEA for inclusion of
placebo in comparative RCTs are plenty but, seemingly,
clinical investigators and the pharmaceutical industry need
to be informed more about why these rules should be
followed. The most important fact to be aware of is the
“effectiveness” of placebo in drug RCTs in migraine. Thus,
in acute RCTs with oral triptans the placebo response for
headache relief at 2 h varied from 17 to 50% [1]. In prophy-
lactic RCTs the placebo-response is usually in the 20 to
40% range but 50% and even 70% [2]have been reported. So
if two “active” drugs both show similar response rates of
45% and 49% in a prophylactic RCT in migraine one cannot
speak of equivalence even with narrow confidence intervals
because no “pharmacological “ effect has been demon-
strated in the patient sample. What is observed in this RCT
could be pure placebo effect or time-effect (regression
toward the mean). Thus the RCT has been performed in
vain. In addition, placebo control is needed for characteriza-
tion of the tolerability of new drugs. Finally, a comparative
“equivalence” RCT without placebo cannot be used in
meta-analysis and does not add to sound scientific knowl-
edge of the drug.
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